Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
- DOI
- 10.1016/s0140-6736(24)01927-5
- Published
- 2025 Jan 4
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-24-01927-5,
title = {Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.},
author = {Rubin DT and Allegretti JR and Panés J and Shipitofsky N and Yarandi SS and Huang KG and Germinaro M and Wilson R and Zhang H and Johanns J and Feagan BG and Hisamatsu T and Lichtenstein GR and Bressler B and Peyrin-Biroulet L and Sands BE and Dignass A and QUASAR Study Group},
year = {2025},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(24)01927-5},
url = {https://doi.org/10.1016/s0140-6736(24)01927-5}
}RIS
TY - JOUR TI - Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. AU - Rubin DT AU - Allegretti JR AU - Panés J AU - Shipitofsky N AU - Yarandi SS AU - Huang KG AU - Germinaro M AU - Wilson R AU - Zhang H AU - Johanns J AU - Feagan BG AU - Hisamatsu T AU - Lichtenstein GR AU - Bressler B AU - Peyrin-Biroulet L AU - Sands BE AU - Dignass A AU - QUASAR Study Group PY - 2025 JO - Lancet (London, England) DO - 10.1016/s0140-6736(24)01927-5 UR - https://doi.org/10.1016/s0140-6736(24)01927-5 ER -
APA
DT, R., JR, A., J, P., N, S., SS, Y., KG, H., M, G., R, W., H, Z., J, J., BG, F., T, H., GR, L., B, B., L, P., BE, S., A, D., & Group, Q. S. (2025). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(24)01927-5
Source records
- pubmed · retrieved 2026-09-25T20:31:56.523Z